First Global Study to Examine Therapy for Patients with Single-Ventricle Cardiac Defect Begins
Clinical trial targets congenital heart disease patients with failing Fontan circulation
Newswise — Toronto, ON (April 12, 2018) – Select adult patients born with a single functioning ventricle (pumping chamber of the heart), and who have undergone a surgical operation called the ‘Fontan procedure’ during childhood, are now being enrolled in a global first clinical trial, led by a multi-disciplinary team of heart and lung physicians, to examine the effects of a portable, non-invasive medical device never before tested on patients with this cardiac condition.
“As the exclusive global site for this important device therapy study, our investigators will be able to select specific complex congenital heart disease patients from the largest cohort of Fontan repair survivors in the world,” says Dr. Barry Rubin, Medical Director, Peter Munk Cardiac Centre (PMCC), University Health Network. “This trial, funded in part by our PMCC Innovation Committee, provides access to suitable patients as well as in-house clinical trials expertise, equipping our medical team with the critical tools necessary to potentially unravel a decades-old medical challenge in congenital cardiology --- supporting those patients whose survival into adulthood is often accompanied by a poor quality of life, often leading to sudden death.”
The study entitled, FONTAN-CMR (Feasibility and efficacy Of Negative Pressure Ventilation in The Ambulatory populatioN-Cardiovascular flow assessment by Magnetic Resonance imaging), will test a portable ventilation system to assist breathing and augment the circulation of a Fontan patient living with only one effective pumping chamber. This study is also supported by the Labatt Family Heart Centre Innovation Fund at SickKids Hospital.
“Adults with a Fontan circulation are at high-risk of cardiac complications which can be caused by the body’s adaptive response to decades of increased pressures in the Fontan circuit,” says Dr. Rachel Wald, adult congenital and paediatric cardiologist, Peter Munk Cardiac Centre and co-principal investigator of the study. “Short of cardiac transplantation, which can be accomplished in relatively few patients, we are left with extremely limited therapies to offer patients when complications begin as a result of failing Fontan physiology. It is our hope that this device will effectively enhance cardiac output, and in doing so, might one day be considered a future bridge to cardiac transplantation or perhaps even destination therapy.”
“Patients with ‘failing Fontan physiology’ will present with fatigue, decreased exercise tolerance, rhythm abnormalities and accumulation of fluid in their limbs and/or abdomen,” says Dr. Pradeepkumar Charla, adult congenital cardiology fellow, Toronto General Hospital, and co-principal investigator of the study. “A chronic, low cardiac output state coupled with increased venous congestion often results in these patients developing multi-organ dysfunction which typically affects the liver and kidneys,” he says.
“The Hayek RTX uses Biphasic Cuirass Ventilation (BCV) to provide an efficient and effective method of non-invasive external ventilation. BCV mimics the natural physiology of spontaneous ventilation with an active expiratory phase,” says Dr. Joseph Cronin, Medical Director, United Hayek Medical, the exclusive manufacturer of the Hayek RTX. “BCV is the only means of cardio-pulmonary support that functions in a truly physiologic way, increasing cardiac output. The ventilator operates via an external cuirass, or shield, which can be worn by patients while awake or asleep, in or out of the hospital.
The initial phase of FONTAN-CMR is designed to explore the safety and efficacy of the portable ventilator to improve cardiac output in adult Fontan survivors using CMR to precisely measure flows into and out of the heart. Study participants have been selected from more than 350 Fontan patients in the adult congenital heart program at PMCC, which has a database of more than 9,000 actively followed adult patients who were born with a heart defect. Phases two and three of the trial will allow children and adults to wear this device for longer periods of time while at home. -30-
ABOUT THE PETER MUNK CARDIAC CENTRE The Peter Munk Cardiac Centre is the premier cardiac centre in Canada. Since it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world. Each year, more than 55,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any other hospital in Canada. The Centre is based at the Toronto General Hospital and the Toronto Western Hospital - members of University Health Network. www.petermunkcardiaccentre.ca